What's driving the Recombinant Vaccines Market Growth? Prominent Players: GlaxoSmithKline plc., Merck & Co., Inc, Pfizer Inc, Dynavax Technologies, Sanofi, Serum Institute of India Pvt. Ltd, Novartis AG, Other Prominent Players

The global recombinant vaccines market size is projected to reach USD 21.00 billion by the end of 2026. The advancements in molecular genomics have opened up a huge potential for market growth. According to a report by Fortune Business Insights, titled "Recombinant Vaccines Market Size, Share & Industry Analysis, By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus, Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2019-2026," the market size was USD 8.97 billion in 2018. Driven by increasing number of regulatory approvals, the market will exhibit a CAGR of 11.3% during the forecast period, 2019-2026

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/recombinant-vaccines-market-101935

Leading Players operating in the Recombinant Vaccines Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

o GlaxoSmithKline plc.
o Merck & Co., Inc
o Pfizer Inc
o Dynavax Technologies
o Sanofi
o Serum Institute of India Pvt. Ltd
o Novartis AG
o Other Prominent Players
Increasing Number of Regulatory Approvals Will Aid Growth
The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the increasing number of regulatory clearances have made the highest impact on the market in recent years. In December 2019, Merck received approval from the US Food and Drug Administration for a new vaccine. The ERVEBO was the first ever Ebola vaccine. The approval for ERVEBO will encourage several manufacturers. In October 2017, the USFDA approved GlaxoSmithKline's new vaccine SHINGRIX which is used for the treatment of herpes zoster. The report highlights the importance of these vaccines on the global market. The report includes a few of the other drug approvals of recent years and gauges their impact on the market.

Detailed Table of Content:

o GlaxoSmithKline plc.
o Merck & Co., Inc
o Pfizer Inc
o Dynavax Technologies
o Sanofi
o Serum Institute of India Pvt. Ltd
o Novartis AG
o Other Prominent Players

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/recombinant-vaccines-market-101935

Market Segmentation:

By Type
o Subunit
o Live Attenuated
By Route of Administration
o Parenteral
o Oral
By Disease Indication
o Human Papillomavirus
o Hepatitis B
o Rotavirus
o Herpes Zoster
o Meningococcal B
o Others
By Distribution Channel
o Hospitals & Retail Pharmacies
o Government Suppliers
o Others
By Geography
o North America (U.S. and Canada)
o Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
o Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
o Latin America (Brazil, Mexico, and Rest of Latin America)
o Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Reasons to Purchase this Report:

o Comprehensive analysis of the Recombinant Vaccines Market growth drivers, obstacles, opportunities, and other related challenges.
o Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
o Identifies market restraints and boosters.
o Identifies all the possible segments present in the market to aid organizations in strategic business planning.

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.